Or­bimed part­ner in search of a cure for Parkin­son’s launch­es new gene ther­a­py play­er

Jonathan Sil­ver­stein is ac­tive­ly look­ing for a biotech mir­a­cle.

The Or­bimed part­ner formed a non­prof­it group called the Sil­ver­stein Foun­da­tion af­ter he was di­ag­nosed with Parkin­son’s, and now he’s launch­ing a new biotech which he hopes can pro­vide just that.

The new biotech is called Pre­vail Ther­a­peu­tics. Based in New York, it will be run by Co­lum­bia Uni­ver­si­ty’s Asa Abe­liovich, look­ing to de­vel­op gene ther­a­pies that will try to cor­rect a dis­ease that has proven to be one of the tough­est tar­gets in drug de­vel­op­ment. Or­bimed and the foun­da­tion — which Sil­ver­stein is al­so fund­ing — are back­ing the start­up along with Re­genXBio, one of the lead­ers in AAV tech used in the gene ther­a­pies now in clin­i­cal de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER